Rhythm Pharmaceuticals, Inc. (RYTM)
119.04
+2.43
(+2.08%)
USD |
NASDAQ |
Nov 18, 16:00
119.19
+0.15
(+0.13%)
After-Hours: 20:00
Rhythm Pharmaceuticals Enterprise Value : 8.150B for Nov. 18, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 18, 2026 | 8.150B |
| November 17, 2026 | 7.982B |
| November 16, 2026 | 7.349B |
| November 13, 2026 | 7.871B |
| November 12, 2026 | 7.514B |
| November 11, 2026 | 7.673B |
| November 10, 2026 | 7.797B |
| November 09, 2026 | 7.797B |
| November 06, 2026 | 7.681B |
| November 05, 2026 | 7.178B |
| November 04, 2026 | 7.571B |
| November 03, 2026 | 5.890B |
| November 02, 2026 | 6.376B |
| October 30, 2026 | 6.315B |
| October 29, 2026 | 6.350B |
| October 28, 2026 | 6.274B |
| October 27, 2026 | 6.288B |
| October 26, 2026 | 6.100B |
| October 23, 2026 | 6.087B |
| October 22, 2026 | 6.200B |
| October 21, 2026 | 6.041B |
| October 20, 2026 | 6.151B |
| October 19, 2026 | 6.014B |
| October 16, 2026 | 5.872B |
| October 15, 2026 | 5.996B |
| Date | Value |
|---|---|
| October 14, 2026 | 5.909B |
| October 13, 2026 | 5.902B |
| October 12, 2026 | 6.125B |
| October 09, 2026 | 6.191B |
| October 08, 2026 | 6.112B |
| October 07, 2026 | 6.030B |
| October 06, 2026 | 6.191B |
| October 05, 2026 | 6.307B |
| October 02, 2026 | 6.333B |
| October 01, 2026 | 6.374B |
| September 30, 2026 | 6.499B |
| September 29, 2026 | 6.480B |
| September 28, 2026 | 6.676B |
| September 25, 2026 | 6.683B |
| September 24, 2026 | 6.659B |
| September 23, 2026 | 6.654B |
| September 22, 2026 | 6.725B |
| September 21, 2026 | 6.694B |
| September 18, 2026 | 6.617B |
| September 17, 2026 | 6.707B |
| September 16, 2026 | 6.638B |
| September 15, 2026 | 6.553B |
| September 14, 2026 | 6.943B |
| September 11, 2026 | 7.099B |
| September 10, 2026 | 6.926B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Alnylam Pharmaceuticals, Inc. | 19.41B |
| Arrowhead Pharmaceuticals, Inc. | 6.299B |
| BioMarin Pharmaceutical, Inc. | 15.37B |
| Cytokinetics, Inc. | 7.284B |
| Exelixis, Inc. | 15.98B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -41.37M |
| Revenue (Quarterly) | 92.13M |
| Total Expenses (Quarterly) | 133.50M |
| EPS Diluted (Quarterly) | -0.6134 |
| Gross Profit Margin (Quarterly) | 86.74% |
| Profit Margin (Quarterly) | -44.90% |
| Earnings Yield | -2.45% |
| Normalized Earnings Yield | -2.439 |